Skip to main content
Erschienen in: Clinical and Experimental Nephrology 6/2020

08.02.2020 | Original article

Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study

verfasst von: Yusuke Ushio, Hiroshi Kataoka, Masayo Sato, Shun Manabe, Saki Watanabe, Taro Akihisa, Shiho Makabe, Rie Yoshida, Ken Tsuchiya, Kosaku Nitta, Toshio Mochizuki

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Though anemia is a sign of poor renal prognosis in chronic kidney disease (CKD), hemoglobin (Hb) levels are typically higher in autosomal dominant polycystic kidney disease (ADPKD) than in other kidney diseases, and anemia has not been examined as a potential prognosticator. Thus, we investigated anemia as a factor for renal prognosis in ADPKD.

Methods

In total, 115 non-dialysis patients, 48 men and 67 women, with ADPKD were evaluated. The renal outcome of a 50% reduction in the estimated glomerular filtration rate or renal replacement therapy was examined using the Cox regression analysis and Kaplan–Meier analysis.

Results

Patients were followed for a median of 5.5 years and 50 patients had reached the end point. The mean age of the patients at the first visit was 45.9 ± 13.3 years. The overall mean Hb was 12.90 ± 1.85 g/dL, and the mean Hb in men and women was 13.82 ± 1.72 g/dL and 12.25 ± 1.65 g/dL, respectively. Hb levels and uric protein content were statistically significant factors for poor renal prognosis, while hypertension and genetic mutations failed to reach significance. Furthermore, statistical significance was found in men with Hb < 12 g/dL and in women with Hb < 11 g/dL. Anemia had significant association with kidney disease progression in patients with ADPKD.

Conclusions

We found that anemia might be a factor for poor renal prognosis in ADPKD. Furthermore, a sex difference was found, wherein men with Hb < 12 g/dL and women with Hb < 11 g/dL were at risk of renal disease progression.
Literatur
1.
Zurück zum Zitat Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17:317–26.CrossRef Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17:317–26.CrossRef
2.
Zurück zum Zitat Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol JASN. 1997;8:1560–7.PubMed Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol JASN. 1997;8:1560–7.PubMed
3.
Zurück zum Zitat Cornec-Le Gall E, Audrezet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, Morin MP, Moal MC, Dantal J, Wehbe B, Perrichot R, Frouget T, Vigneau C, Potier J, Jousset P, Guillodo MP, Siohan P, Terki N, Sawadogo T, Legrand D, Menoyo-Calonge V, Benarbia S, Besnier D, Longuet H, Ferec C, Le Meur Y. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol JASN. 2016;27:942–51.CrossRef Cornec-Le Gall E, Audrezet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, Morin MP, Moal MC, Dantal J, Wehbe B, Perrichot R, Frouget T, Vigneau C, Potier J, Jousset P, Guillodo MP, Siohan P, Terki N, Sawadogo T, Legrand D, Menoyo-Calonge V, Benarbia S, Besnier D, Longuet H, Ferec C, Le Meur Y. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol JASN. 2016;27:942–51.CrossRef
4.
Zurück zum Zitat Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, Pereira BJ. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38:803–12.CrossRef Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, Pereira BJ. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38:803–12.CrossRef
5.
Zurück zum Zitat Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol JASN. 1999;10:1793–800.PubMed Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol JASN. 1999;10:1793–800.PubMed
6.
Zurück zum Zitat Portoles J, Gorriz JL, Rubio E, de Alvaro F, Garcia F, Alvarez-Chivas V, Aranda P, Martinez-Castelao A, Group N-S. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2.CrossRef Portoles J, Gorriz JL, Rubio E, de Alvaro F, Garcia F, Alvarez-Chivas V, Aranda P, Martinez-Castelao A, Group N-S. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2.CrossRef
7.
Zurück zum Zitat Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, Investigators C. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.CrossRef Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, Investigators C. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.CrossRef
8.
Zurück zum Zitat Chang WX, Asakawa S, Toyoki D, Nemoto Y, Morimoto C, Tamura Y, Ota T, Shibata S, Fujigaki Y, Shen ZY, Uchida S. Predictors and the subsequent risk of end-stage renal disease—usefulness of 30% decline in estimated GFR over 2 years. PLoS ONE ONE. 2015;10:e0132927.CrossRef Chang WX, Asakawa S, Toyoki D, Nemoto Y, Morimoto C, Tamura Y, Ota T, Shibata S, Fujigaki Y, Shen ZY, Uchida S. Predictors and the subsequent risk of end-stage renal disease—usefulness of 30% decline in estimated GFR over 2 years. PLoS ONE ONE. 2015;10:e0132927.CrossRef
9.
Zurück zum Zitat Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O'Donoghue DJ, Foley RN, Middleton RJ. Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis. 2010;56:1072–81.CrossRef Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O'Donoghue DJ, Foley RN, Middleton RJ. Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis. 2010;56:1072–81.CrossRef
10.
Zurück zum Zitat Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, Hegarty J, New J, O'Donoghue DJ, Middleton RJ, Kalra PA. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol CJASN. 2010;5:2251–7.CrossRef Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, Hegarty J, New J, O'Donoghue DJ, Middleton RJ, Kalra PA. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol CJASN. 2010;5:2251–7.CrossRef
11.
Zurück zum Zitat Tsuruya K, Yoshida H, Suehiro T, Fujisaki K, Masutani K, Kitazono T. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin. Ren Fail. 2016;38:390–6.CrossRef Tsuruya K, Yoshida H, Suehiro T, Fujisaki K, Masutani K, Kitazono T. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin. Ren Fail. 2016;38:390–6.CrossRef
12.
Zurück zum Zitat Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination survey (1988–1994). Arch Intern Med. 2002;162:1401–8.CrossRef Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination survey (1988–1994). Arch Intern Med. 2002;162:1401–8.CrossRef
13.
Zurück zum Zitat Okada K, Yanai M, Takeuchi K, Matsuyama K, Nitta K, Hayashi K, Takahashi S. Sex differences in the prevalence, progression, and improvement of chronic kidney disease. Kidney Blood Press Res. 2014;39:279–88.CrossRef Okada K, Yanai M, Takeuchi K, Matsuyama K, Nitta K, Hayashi K, Takahashi S. Sex differences in the prevalence, progression, and improvement of chronic kidney disease. Kidney Blood Press Res. 2014;39:279–88.CrossRef
14.
Zurück zum Zitat Mochizuki T, Teraoka A, Akagawa H, Makabe S, Akihisa T, Sato M, Kataoka H, Mitobe M, Furukawa T, Tsuchiya K, Nitta K. Mutation analyses by next-generation sequencing and multiplex ligation-dependent probe amplification in Japanese autosomal dominant polycystic kidney disease patients. Clin Exp Nephrol. 2019. https://doi.org/10.1007/s10157-019-01736-3.CrossRefPubMed Mochizuki T, Teraoka A, Akagawa H, Makabe S, Akihisa T, Sato M, Kataoka H, Mitobe M, Furukawa T, Tsuchiya K, Nitta K. Mutation analyses by next-generation sequencing and multiplex ligation-dependent probe amplification in Japanese autosomal dominant polycystic kidney disease patients. Clin Exp Nephrol. 2019. https://​doi.​org/​10.​1007/​s10157-019-01736-3.CrossRefPubMed
15.
Zurück zum Zitat Ording AG, Sorensen HT. Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogs. Clin Epidemiol. 2013;5:199–203.CrossRef Ording AG, Sorensen HT. Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogs. Clin Epidemiol. 2013;5:199–203.CrossRef
16.
Zurück zum Zitat Woon C, Bielinski-Bradbury A, O'Reilly K, Robinson P. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2015;16:140.CrossRef Woon C, Bielinski-Bradbury A, O'Reilly K, Robinson P. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2015;16:140.CrossRef
17.
Zurück zum Zitat Griveas I, Bishop K, World M. Adult polycystic kidney disease: who needs hospital follow-up? Artif Organs. 2012;36:594–9.CrossRef Griveas I, Bishop K, World M. Adult polycystic kidney disease: who needs hospital follow-up? Artif Organs. 2012;36:594–9.CrossRef
18.
Zurück zum Zitat Panizo N, Goicoechea M, Garcia de Vinuesa S, Arroyo D, Yuste C, Rincon A, Verdalles U, Ruiz-Caro C, Quiroga B, Luno J. Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease. Nefrologia. 2012;32:197–205.PubMed Panizo N, Goicoechea M, Garcia de Vinuesa S, Arroyo D, Yuste C, Rincon A, Verdalles U, Ruiz-Caro C, Quiroga B, Luno J. Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease. Nefrologia. 2012;32:197–205.PubMed
19.
Zurück zum Zitat de Almeida EA, Alho I, Marques F, Thiran C, Bicho MP, Prata M. Haemoglobin and erythropoietin levels in polycystic kidney disease. Nephrol Dial Transplant. 2008;23:412–3.CrossRef de Almeida EA, Alho I, Marques F, Thiran C, Bicho MP, Prata M. Haemoglobin and erythropoietin levels in polycystic kidney disease. Nephrol Dial Transplant. 2008;23:412–3.CrossRef
20.
Zurück zum Zitat Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron. 1985;39:26–9.CrossRef Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron. 1985;39:26–9.CrossRef
21.
Zurück zum Zitat Eckardt KU, Mollmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U, et al. Erythropoietin in polycystic kidneys. J Clin Investig. 1989;84:1160–6.CrossRef Eckardt KU, Mollmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U, et al. Erythropoietin in polycystic kidneys. J Clin Investig. 1989;84:1160–6.CrossRef
22.
Zurück zum Zitat Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365:537–47.CrossRef Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365:537–47.CrossRef
23.
Zurück zum Zitat Liu J, Wei Q, Guo C, Dong G, Liu Y, Tang C, Dong Z. Hypoxia, HIF, and associated signaling networks in chronic kidney disease. Int J Mol Sci. 2017;18(5):950.CrossRef Liu J, Wei Q, Guo C, Dong G, Liu Y, Tang C, Dong Z. Hypoxia, HIF, and associated signaling networks in chronic kidney disease. Int J Mol Sci. 2017;18(5):950.CrossRef
24.
Zurück zum Zitat Kraus A, Peters DJM, Klanke B, Weidemann A, Willam C, Schley G, Kunzelmann K, Eckardt KU, Buchholz B. HIF-1alpha promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2018;94:887–99.CrossRef Kraus A, Peters DJM, Klanke B, Weidemann A, Willam C, Schley G, Kunzelmann K, Eckardt KU, Buchholz B. HIF-1alpha promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2018;94:887–99.CrossRef
25.
Zurück zum Zitat Hofherr A, Busch T, Kottgen M. HIF-1alpha drives cyst growth in advanced stages of autosomal dominant polycystic kidney disease. Kidney Int. 2018;94:849–51.CrossRef Hofherr A, Busch T, Kottgen M. HIF-1alpha drives cyst growth in advanced stages of autosomal dominant polycystic kidney disease. Kidney Int. 2018;94:849–51.CrossRef
26.
Zurück zum Zitat Buchholz B, Schley G, Faria D, Kroening S, Willam C, Schreiber R, Klanke B, Burzlaff N, Jantsch J, Kunzelmann K, Eckardt KU. Hypoxia-inducible factor-1alpha causes renal cyst expansion through calcium-activated chloride secretion. J Am Soc Nephrol JASN. 2014;25:465–74.CrossRef Buchholz B, Schley G, Faria D, Kroening S, Willam C, Schreiber R, Klanke B, Burzlaff N, Jantsch J, Kunzelmann K, Eckardt KU. Hypoxia-inducible factor-1alpha causes renal cyst expansion through calcium-activated chloride secretion. J Am Soc Nephrol JASN. 2014;25:465–74.CrossRef
27.
Zurück zum Zitat Murphy WG. The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences. Blood Rev. 2014;28:41–7.CrossRef Murphy WG. The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences. Blood Rev. 2014;28:41–7.CrossRef
28.
Zurück zum Zitat Sakashita M, Tanaka T, Nangaku M. Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors to treat anemia in chronic kidney disease. Contrib Nephrol. 2019;198:112–23.CrossRef Sakashita M, Tanaka T, Nangaku M. Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors to treat anemia in chronic kidney disease. Contrib Nephrol. 2019;198:112–23.CrossRef
29.
Zurück zum Zitat Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12:157–68.CrossRef Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12:157–68.CrossRef
Metadaten
Titel
Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study
verfasst von
Yusuke Ushio
Hiroshi Kataoka
Masayo Sato
Shun Manabe
Saki Watanabe
Taro Akihisa
Shiho Makabe
Rie Yoshida
Ken Tsuchiya
Kosaku Nitta
Toshio Mochizuki
Publikationsdatum
08.02.2020
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 6/2020
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-020-01856-1

Weitere Artikel der Ausgabe 6/2020

Clinical and Experimental Nephrology 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.